FrancophonIA/ELRC3.0 huggingface dataset:
English: Biograstim and bone marrow transplantation
Croatian: Biograstim i presađivanje koštane srži
English: Regular monitoring of platelet count and haematocrit is recommended.
Croatian: Preporučuju se redovite kontrole hematokrita i broja trombocita.
English: The first dose of filgrastim should not be administered less than 24 hours following cytotoxic chemotherapy.
Croatian: Prva doza filgrastima smije se dati najranije 24 sata nakon citotoksične kemoterapije.
English: The recommended starting dose of filgrastim is 0.1 MIU (1 μg)/kg/day given daily by subcutaneous injection with titration up to a maximum of 0.4 MIU (4 μg)/kg/day until a normal neutrophil count is
Croatian: Preporučena početna doza je 0,1 MIU (1 μg)/kg/dan svakoga dana u supkutanoj injekciji, i može se titrirati do najviše 0,4 MIU (4 μg)/kg/dan, do postizanja normalnog broja neutrofila, koji će biti moguće i održavati (ABN > 2,0 x 109/l).
English: Long-term treatment with Biograstim is required for neutropenia.
Croatian: Pri neutropeniji je nužna dugotrajnija primjena lijeka Biograstim.
English: Common (may affect up to 1 in 10 people): - reduction in blood platelets, which increases risk of bleeding or bruising; - headache; - diarrhoea; - enlargement of the liver; - hair loss; inflammation of blood vessels, often with skin rash; pain at the site of injection; rash; - loss of calcium from the bones; joint pain.
Croatian: Često (mogu se javiti do 1 na 10 osoba): - smanjeni broj trombocita u krvi, zbog čega se može povećati mogućnost pojave krvarenja ili modrica; - glavobolja; - proljev; - povećanje jetre; - ispadanje kose; upala krvnih žila, često uz kožni osip;bol na mjestu injekcije; osip; - gubitak kalcija iz kostiju; bol u zglobovima.
English: The degree of variation between individual patients and between laboratory assays of CD34
Croatian: Stupanj varijacije između pojedinih bolesnika i između laboratorijskih metoda brojenja CD34+ stanica pokazuje da je izravna usporedba između ispitivanja teška.
English: 9/L prior to leukapheresis; in general apheresis should not be performed if platelets < 100 x 10
Croatian: Treba li obaviti više od jedne leukafereze, nužan je poseban oprez u davatelja s trombocitima < 100 x 109/l prije leukafereze; aferezu općenito ne treba izvoditi ako su trombociti < 75 x 109/l.
English: For the mobilisation of PBPC in patients undergoing myelosuppressive or myeloablative therapy followed by autologous peripheral blood progenitor cell transplantation
Croatian: Za mobilizaciju progenitorskih stanica periferne krvi u bolesnika s presađenim autolognim progenitorskim stanicama periferne krvi nakon mijelosupresijske ili mijeloablacijske terapije
English: 9/L, and a history of severe or recurrent infections, long absolute neutrophil count (ANC) of ≤ 0.5 x 10 term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Croatian: U bolesnika, djece i odraslih, s teškom kongenitalnom cikličkom ili idiopatskom neutropenijom i apsolutnim brojem neutrofila (ABN) ≤ 0,5 x 109/l, kao i s teškim ili rekurentnim infekcijama u anamnezi, dugotrajna primjena Biograstim se koristi za povećanje broja neutrofila i za smanjenje incidencije i skraćivanje trajanja događaja povezanih s infekcijama.
English: Isolated cases of sickle cells crises have been reported in patients with sickle cell disease (see section 4.4).
Croatian: U bolesnika s anemijom srpastih stanica (vidjeti dio 4.4) prijavljeni su izolirani slučajevi kriza srpastih stanica.
English: - The active substance is filgrastim.
Croatian: Što Biograstim sadrži - Djelatna tvar je filgrastim.
English: Elevated alkaline phosphatase, elevated LDH, elevated uric acid
Croatian: Povišena alkalna fosfataza, povišena LDH, povišena mokraćna kiselina
English: For infusions, filgrastim should be diluted in 20 mL of glucose 50 mg/mL (5 %) solution for infusion (see section 6.6 for instructions on dilution).
Croatian: Za infuziju je filgrastim potrebno razrijediti u 20 ml 50 mg/ml (5 %) otopine glukoze za infuziju (za upute o razrjeđivanju vidjeti dio 6.6).
English: Established cytotoxic chemotherapy
Croatian: Utvrđeni protokol citotoksične kemoterapije
English: The most commonly reported undesirable effect was mild to moderate transient musculo-skeletal pain.
Croatian: Najčešće prijavljivana nuspojava bila je blaga do umjerena, prolazna bol u mišićno-koštanom sustavu.
English: Talk to your doctor or nurse that you are treated with Biograstim if you are undergoing bone-imaging.
Croatian: U slučaju snimanja kostiju recite liječniku ili medicinskoj sestri da se liječite Biograstimom.
English: Biograstim 30 MIU/0.5 mL solution for injection or infusion Filgrastim
Croatian: Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju filgrastim
English: Subcutaneous use and intravenous use.
Croatian: Za potkožnu primjenu i primjenu u venu.
English: Packs containing 1, 5 or 10 pre-filled syringes with 0.5 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.5 mL solution.
Croatian: Pakiranje sadrži 1, 5 ili 10 napunjenih štrcaljki s 0,5 ml otopine ili višestruka pakiranja s 10 (2 pakiranja od 5) napunjenih štrcaljki s 0,5 ml otopine.
English: The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.
Croatian: Pokazalo se da progenitorske stanice periferne krvi, mobilizirane filgrastimom, smanjuju jačinu i skraćuju trajanje trombocitopenije nakon mijelosupresijske ili mijeloablacijske kemoterapije.
English: Special precautions in sickle cell disease
Croatian: Posebne mjere opreza pri bolesti srpastih stanica
English: Packs containing 1, 5 or 10 pre-filled syringes with 0.8 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.8 mL solution.
Croatian: Pakiranje sadrži 1, 5 ili 10 napunjenih štrcaljki s 0,8 ml otopine ili višestruka pakiranja s 10 (2 pakiranja od 5) napunjenih štrcaljki s 0,5 ml otopine.
English: EU/1/08/450/001 1 pre-filled syringe EU/1/08/450/002 5 pre-filled syringes EU/1/08/450/004 10 pre-filled syringes EU/1/08/450/009 5 pre-filled syringes with safety device
Croatian: EU/1/08/450/001 1 napunjena štrcaljka EU/1/08/450/002 5 napunjenih štrcaljki EU/1/08/450/004 10 napunjenih štrcaljki EU/1/08/450/009 5 napunjenih štrcaljki sa zaštitom za iglu
English: Haematuria/proteinuria occurred in a small number of patients.
Croatian: U malog broja bolesnika javila se hematurija/proteinurija.
English: 9/L during the treatment period the dose of filgrastim should be reescalated according to the above steps
Croatian: Smanji li se ABN tijekom trajanja terapije na < 1,0 x 109/l, dozu filgrastima treba ponovno povećavati u skladu s gornjom shemom.
English: Daily dosing with filgrastim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.
Croatian: Filgrastim treba davati svakodnevno, sve dok ne prođe razdoblje očekivanih najnižih vrijednosti broja neutrofila i dok se njihov broj ne normalizira.
English: cannot be estimated from the available data Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Croatian: U svakoj skupini prema učestalosti, nuspojave su navedene silaznim slijedom prema ozbiljnosti.
English: However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals
Croatian: No sa stajališta mogućih rizika povezanih s jakom leukocitozom, pri terapiji filgrastimom potrebno je u redovitim vremenskim razmacima, provjeravati broj leukocita.
English: In normal stem cell donors
Croatian: U zdravih davatelja matičnih stanica
English: 9/L) was observed in 41 % of donors and transient 9/L) following filgrastim and leukapheresis was observed in thrombocytopenia (platelets < 100 x 10
Croatian: Leukocitoza (leukociti > 50 x 109/l) je uočena u 41 %, a prolazna trombocitopenija (trombociti < 100 x 109/l) u 35 % davatelja nakon primjene filgrastima i leukafereze.
English: Sixty-five percent of the patients studied in the SCN trial programme were under 18 years of age.
Croatian: Pedijatrijska primjena u bolesnika s teškom kroničnom neutropenijom i u onkoloških bolesnika Šezdeset pet posto bolesnika uključenih u program ispitivanja teške kronične neutropenije bilo je mlađe od 18 godina.
English: Special precautions in normal donors undergoing peripheral blood progenitor cell mobilisation
Croatian: Posebne mjere opreza u zdravih davatelja u kojih se obavlja mobilizacija progenitorskih stanica periferne krvi
English: EU/1/08/450/005 1 pre-filled syringe EU/1/08/450/006 5 pre-filled syringes EU/1/08/450/008 10 pre-filled syringes EU/1/08/450/010 5 pre-filled syringes with safety device
Croatian: EU/1/08/450/005 1 napunjena štrcaljka EU/1/08/450/006 5 napunjenih štrcaljki EU/1/08/450/008 10 napunjenih štrcaljki EU/1/08/450/010 5 napunjenih štrcaljki sa zaštitom za iglu
English: Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high dose chemotherapy followed by autologous bone marrow transplantation.
Croatian: U bolesnika kojima je presađena koštana srž nakon prethodne primjene velikih doza kemoterapije bilo je povremenih prijava poremećaja krvnih žila, uključujući venookluzivnu bolest i poremećaje volumena tekućine.
English: Dispose of syringes with safety device as instructed by your doctor, nurse or pharmacist.
Croatian: Štrcaljku zbrinite kako su Vam objasnili liječnik, medicinska sestra ili ljekarnik.
English: Biograstim 48 MIU/0.8 mL solution for injection or infusion Filgrastim
Croatian: Biograstim 48 MIU/0,8 ml otopina za injekciju ili infuziju filgrastim
English: Box for the prescribed dose
Croatian: Prostor za preporučeno doziranje
English: Allergic Reactions: Allergic-type reactions, including anaphylaxis, skin rash, urticaria, angioedema, dyspnoea and hypotension, occurring on initial or subsequent treatment, have been reported in patients receiving filgrastim.
Croatian: Alergijske reakcije: U bolesnika koji su primali filgrastim prijavljivane su alergijske reakcije na početku primjene ili pri kasnijoj primjeni, uključujući anafilaksiju, kožni osip, urtikariju, angioedem, dispneju i hipotenziju.
English: Special precautions in patients undergoing peripheral blood progenitor cell mobilisation Mobilisation
Croatian: Posebne mjere opreza u bolesnika u kojih se obavlja mobilizacija progenitorskih stanica periferne krvi
English: Transient cytogenic modifications have been observed in normal donors following G-CSF use.
Croatian: U zdravih davatelja koji su primali G-CSF uočene su prolazne citogenetske promjene.
English: Solution for injection or infusion Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.8 mL.
Croatian: Višestruko pakiranje: 10 (2 pakiranja od 5) napunjenih štrcaljki koje sadrže 0,8 ml.
English: Alopecia, skin rash Sweet's syndrome, cutaneous vasculitis
Croatian: Sweetov sindrom, kožni vaskulitis
English: Each mL of solution for injection or infusion contains 60 million international units [MIU] (600 µg) of filgrastim.
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV Jedan ml otopine za injekciju ili infuziju sadrži 60 milijuna internacionalnih jedinica [MIU] (600 μg) filgrastima.
English: The following undesirable effects and their frequencies have been observed under treatment with filgrastim based on published information.
Croatian: Nuspojave prema dosad objavljenim podacima, i njihova učestalost pri primjeni filgrastima niže su navedene.
English: The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation.
Croatian: U bolesnika kojima je nakon mijeloablacijske terapije presađena koštana srž nije se skratilo vrijeme trajanja vrućice.
English: No effect was observed on the fertility of male and female rats or gestation in rats.
Croatian: Filgrastim se nije pokazao teratogenim u štakora i kunića.
English: Solution for injection or infusion Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.5 mL.
Croatian: Višestruko pakiranje: 10 (2 pakiranja od 5) napunjenih štrcaljki koje sadrže 0,5 ml.
English: When the response has been obtained, the reached and can be maintained at more than 1.5 x 10 minimal effective dose to maintain this level should be established.
Croatian: Nakon što se postigne odgovor, treba odrediti minimalnu učinkovitu dozu za održavanje te razine neutrofila.
English: Biograstim 30 MIU/0.5 mL solution for injection or infusion
Croatian: NAZIV LIJEKA Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju
English: Subsequently the dose may be
Croatian: OD LIJEKA AKO JE POTREBNO
English: 2/day (4.0 to 8.4 μg/kg/day) was used.
Croatian: U randomiziranim kliničkim ispitivanjima davala se supkutano doza od 23 MIU (230 μg)/m2/dan (4,0 do 8,4 μg/kg/dan).
English: During long term use, cutaneous vasculitis has been reported in 2 % of SCN patients.
Croatian: Tijekom dugotrajne primjene u 2 % bolesnika s teškom kroničnom neutropenijom prijavljen je vaskulitis.
English: Contents of the pack and other information What Biograstim contains
Croatian: Sadržaj pakiranja i druge informacije
English: A faster schedule of dose escalation may be considered in patients presenting with and 10 x 10 severe infections.
Croatian: U bolesnika s teškim infekcijama može se razmotriti brže prilagođavanje doze.
English: Exacerbation of rheumatoid arthritis has been observed in individual cases.
Croatian: Bilo je pojedinačnih slučajeva egzacerbacije reumatoidnog artritisa.
English: In patients treated with myeloablative therapy followed by bone marrow transplantation
Croatian: Bolesnici s presađenom koštanom srži i prethodnom mijeloablacijskom terapijom
English: Very rare (may affect up to 1 in 10,000 people): - painful, raised, plum-coloured sores on the limbs and sometimes the face and neck with fever
Croatian: Rijetko (mogu se javiti do 1 na 1000 osoba): - vaskularni poremećaji, koji mogu uzrokovati bol, crvenilo i oticanje udova.
English: There was a low frequency (approximately 3 %) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim.
Croatian: U kliničkim ispitivanjima bolesnika s teškom kroničnom neutropenijom koji su primali filgrastim, malom su se učestalošću (oko 3 %) javljali mijelodisplastični sindrom (MDS) ili leukemija.
English: Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently < 100,000/mm
Croatian: U bolesnika koji razviju trombocitopeniju, tj. kada je broj trombocita kontinuirano < 100 000/mm3, potrebno je razmotriti mogućnost povremenih prekida primjene ili smanjenja doze filgrastima.
English: (Sweet's syndrome); inflammation of blood vessels, often with skin rash; - worsening of rheumatic conditions; - pains or difficulties in passing urine.
Croatian: - pojava bolnih, uzdignutih, modro obojenih žarišta po udovima te katkada i po licu i vratu praćenih vrućicom (Sweetov sindrom); upala krvnih žila, često uz kožni osip; - pogoršanje reumatskih stanja; - bolno ili otežano mokrenje.
English: Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medicinal products.
Croatian: Rizik povezan s povećanim dozama mijelosupresijskih lijekova Primjena filgrastima samog ne znači da će se spriječiti pojava trombocitopenije i anemije izazvana primjenom mijelosupresijskih lijekova.
English: Biograstim 48 MIU/0.8 mL solution for injection or infusion
Croatian: NAZIV LIJEKA Biograstim 48 MIU /0,8 ml otopina za injekciju ili infuziju
English: These autologous PBPCs may be harvested and infused after high-dose cytotoxic therapy, either in place of or in addition to bone marrow transplantation.
Croatian: Autologne progenitorske stanice periferne krvi mogu se izdvojiti, i ponovno dati infuzijom nakon velikih doza citotoksične kemoterapije, bilo umjesto presađivanja koštane srži, bilo zajedno s njim.
English: SPECIAL STORAGE CONDITIONS
Croatian: Posebne populacije
English: Rare:
Croatian: Rijetko
English: Filgrastim
Croatian: Proljev
English: Spleen disorder
Croatian: Poremećaj slezene
English: Long-term daily administration is required to maintain an adequate neutrophil count.
Croatian: Za održavanje primjerenog broja neutrofila nužna je dugotrajna primjena lijeka.
English: In peripheral blood progenitor cell mobilisation in normal donors
Croatian: Pri mobilizaciji progenitorskih stanica u perifernoj krvi zdravih davatelja
English: Leukocytosis, thrombocytopenia Spleen disorder
Croatian: Leukocitoza, trombocitopenija
English: Solution for injection or infusion 5 pre-filled syringes containing 0.8 mL.
Croatian: 5 napunjenih štrcaljki koje sadrže 0,8 ml.
English: Biograstim and peripheral blood stem cell mobilisation If you are donating stem cells for yourself, the usual dose is 0.5 million to 1 million international units (MIU) per kilogram bodyweight each day.
Croatian: Ako ćete primiti vlastite matične stanice, uobičajena doza je 0,5 milijuna do 1 milijun internacionalnih jedinica [MIU] po kilogramu tjelesne težine na dan.
English: ≥ 1/1,000 to < 1/100
Croatian: ≥1/100 do <1/10, Manje česte: ≥1/1000 do <1/100, Rijetke:
English: EU/1/08/450/007 2 x 5 pre-filled syringes
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/08/450/007 2 x 5 napunjenih štrcaljki
English: cells/kg is based on published experience resulting in adequate haematologic reconstitution.
Croatian: Preporuka o minimalnom prinosu od 2,0 x 106 CD34+ stanica/kg temelji se na dosad objavljenim iskustvima, u kojima se postigla primjerena hematološka rekonstitucija.
English: Excipients
Croatian: Učestalost
English: In severe chronic neutropenia patients
Croatian: Bolesnici s teškom kroničnom neutropenijom
English: Solution for injection or infusion 5 pre-filled syringes containing 0.5 mL.
Croatian: 5 napunjenih štrcaljki koje sadrže 0,5 ml.
English: EU/1/08/450/003 2 x 5 pre-filled syringes
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/08/450/003 2 x 5 napunjenih štrcaljki
English: Special precautions in recipients of allogeneic PBPC mobilised with filgrastim
Croatian: Posebne mjere opreza u primatelja alogeničnih progenitorskih stanica periferne krvi mobiliziranih filgrastimom
English: Chest pain, musculoskeletal pain
Croatian: Bol u prsištu, bol u mišićnokoštanom sustavu
English: In patients with HIV infection For reversal of neutropenia
Croatian: Bolesnici s HIV-infekcijom
English: Prior to allogeneic PBPC transplantation, use of filgrastim for the mobilisation of PBPC in normal donors allows a collection of 4 x 10
Croatian: Primjenom filgrastima u zdravih davatelja u svrhu mobilizacije progenitorskih stanica periferne krvi prije alogenog presađivanja tih stanica, u većine se davatelja dvjema leukaferezama prikupi 4 x 106 CD34+ stanica po kg tjelesne težine davatelja.
English: Uncommon
Croatian: Kronični
English: Then, if ANC remains > 1.0 x 10
Croatian: Potom, ako je ukupni broj neutrofila >1,0x109/l tijekom najmanje 3 uzastopna dana
English: Transient, minor increases in alkaline phosphatase, LDH, SGOT (serum glutamic oxaloacetic transaminase) and uric acid have been reported in normal donors receiving filgrastim; these were without clinical sequelae.
Croatian: U zdravih davatelja koji su primali filgrastim bilo je prijava prolaznog i slabog povišenja alkalne fosfataze, LDH, AST i mokraćne kiseline; to nije imali nikakvih kliničkih posljedica.
English: 6.6 Special precautions for disposal and other handling
Croatian: 4.4 Posebna upozorenja i mjere opreza pri uporabi
English: 4.8 Undesirable effects Summary of the safety profile
Croatian: Sažetak sigurnosnog profila
English: Very rare events of cutaneous vasculitis have been reported in patients treated with filgrastim.
Croatian: U bolesnika koji su primali filgrastim bilo je vrlo rijetkih prijava kožnog vaskulitisa.
English: Sickle cells crises, in some cases fatal, have been reported with the use of filgrastim in subjects with sickle cell disease.
Croatian: Pri primjeni filgrastima u bolesnika s anemijom srpastih stanica bilo je prijava kriza srpastih stanica, u nekim slučajevima sa smrtnim ishodom.
English: Transformation to leukaemia or myelodysplastic syndrome
Croatian: Nuspojava Leukocitoza, trombocitopenija
English: Prior exposure to cytotoxic agents
Croatian: Prethodno liječenje citotoksičnim pripravcima
English: Special precautions in cancer patients Leukocytosis
Croatian: Posebne mjere opreza u bolesnika s akutnom mijeloičnom leukemijom
English: be required to maintain the ANC > 2.0 x 10
Croatian: Leukaferezu treba obavljati tijekom razdoblja u kojem ABN s < 0,5x109/l poraste na > 5,0 x 109/l.
English: Sickle cell crisis has happened in some patients with Sickle Cell Disease who have been given filgrastim.
Croatian: U nekih bolesnika s anemijom srpastih stanica, koji su uzimali filgrastim, javila se kriza srpastih stanica.
English: Thrombocytopenia
Croatian: Leukocitoza
English: Method of administration
Croatian: NAČIN PRIMJENE LIJEKA
English: In SCN patients
Croatian: U onkoloških bolesnika
English: Information for injecting yourself
Croatian: Informacije za samostalnu primjenu lijeka
English: Your doctor will decide how many days treatment is needed.
Croatian: Vaš liječnik će odlučiti koliko dana liječenja je potrebno.
English: In this situation, you should inform your doctor as soon as possible.
Croatian: U toj situaciji morate što prije obavijestiti svojeg liječnika.
English: Each infusion will last about an hour.
Croatian: Svaka infuzija će trajati oko jedan sat.
English: • If you are a child or growing adolescent below 18 years of age.
Croatian: • ako ste dijete ili adolescent koji raste mlađi od 18 godina.
English: Resistant (R >)
Croatian: Rezistentan (R >)
English: 50131 Florence
Croatian: 50131 Firenca
English: Other types of skin infections have not been studied.
Croatian: Nisu ispitivane druge vrste kožnih infekcija.
English: The total duration of treatment is 5 to 14 days.
Croatian: Ukupno trajanje liječenja je 5 do 14 dana.
English: These adverse reactions may occur following the first dose.
Croatian: Ove se nuspojave mogu pojaviti nakon prve doze.
English: There are no significant circulating metabolites (mean=9.6%) in humans.
Croatian: Nema značajnih cirkulirajućih metabolita (srednja vrijednost=9,6%) u ljudi.
English: • Hearing things that do not exist (auditory hallucination)
Croatian: • čujenje zvukova koji ne postoje (slušne halucinacije)
English: If less than 8 hours remain before the next dose, wait until the next scheduled dose.
Croatian: Ako je do sljedeće doze ostalo manje od 8 sati, tada pričekajte do sljedeće planirane doze.
English: Children or growing adolescents below 18 years of age (see section 4.2).
Croatian: Djeca ili adolescenti koji rastu mlađi od 18 godina (vidjeti dio 4.2).
English: • Decreased appetite
Croatian: • smanjeni apetit
English: It is available in packs containing 10 vials.
Croatian: Dostupan je u pakiranju koje sadrži 10 bočica.
English: • If you are pregnant, might become pregnant, or think you might be pregnant.
Croatian: • ako ste trudni, mogli biste zatrudnjeti ili mislite da biste mogli biti trudni.
English: • Ringing or buzzing in the ears (tinnitus)
Croatian: • zvonjava ili šum u ušima (tinitus)
English: In those cases your doctor will consider if this treatment is the best option for you.
Croatian: Liječnik će u tim slučajevima razmotriti je li ovo liječenje najbolje rješenje za Vas.
English: Gram-positive micro-organisms:
Croatian: Gram-pozitivni mikroorganizmi:
English: EU/1/19/1393/002 10 x 1 tablets EU/1/19/1393/003 20 x 1 tablets EU/1/19/1393/004 30 x 1 tablets EU/1/19/1393/005 50 x 1 tablets EU/1/19/1393/006 60 x 1 tablets EU/1/19/1393/007 100 x 1 tablets
Croatian: EU/1/19/1393/002 10 x 1 tableta EU/1/19/1393/003 20 x 1 tableta EU/1/19/1393/004 30 x 1 tableta EU/1/19/1393/005 50 x 1 tableta EU/1/19/1393/006 60 x 1 tableta EU/1/19/1393/007 100 x 1 tableta
English: AlfaSigma 1 Via Enrico Fermi 65020 Alanno (PE) Italy
Croatian: AlfaSigma 1 Via Enrico Fermi 65020 Alanno (PE) Italija